Advancing Lupus Care: The Changing Landscape of Treatment
The progression toward more targeted, disease-modifying options for the historically difficult rheumatic disease made more headway in 2023.
Stay updated with breaking news from Brad Rovin. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The progression toward more targeted, disease-modifying options for the historically difficult rheumatic disease made more headway in 2023.
Drs Jonathan Barratt and Brad Rovin comment on clinical trial data regarding the use of povetacicept for the treatment of IgAN.
Jonathan Barratt, PhD, FRCP, and Brad Rovin, MD, discuss the future of IgAN treatment, highlighting the BlyS/APRIL axis.
Nephrology experts explore the role of dual inhibition of BlyS and APRIL in the treatment of IgAN, and how this can impact disease pathogenesis.
Jonathan Barratt, PhD, FRCP, and Brad Rovin, MD, review clinical trials for new and emerging treatments for IgAN, highlighting atacicept and telitacicept.